UAE-based BioSapien extends its pre-Series A funding to over USD 8M, with new investor Globivest joining existing backers for its innovative MediChip™ platform.
Jul 07, 2025•9 days ago
Amount Raised
$8 Million
Round Type
PRE-SERIES A
San DiegoTherapeuticsPharmaceuticalMedicalBiotechnologyHealth CareInvestors
Dara HoldingsGolden Gate VenturesGlobal VenturesGlobivest
Description
BioSapien has successfully extended its pre-Series A funding round to over USD 8 million, backed by MENA-based VC firm Globivest. The startup is focused on developing MediChip™, a localized cancer treatment platform. This extension adds to previous investments from Global Ventures, Golden Gate Ventures, and Dara Holdings. Notably, BioSapien aims to minimize systemic toxicity while delivering treatment directly to tumor sites.
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers